Gossamer Bio Under Investigation After 80.1% Stock Plunge Following Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2026
0mins
Should l Buy GOSS?
Source: Businesswire
- Legal Investigation Initiated: The Schall Law Firm has announced an investigation into Gossamer Bio, focusing on potential violations of securities laws, particularly regarding the issuance of false or misleading statements that could affect investor decisions.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its product candidate seralutinib failed to meet its primary endpoint in the Phase 3 PROSERA trial, leading to a significant loss of market confidence.
- Stock Price Plunge: Following this announcement, Gossamer's shares plummeted by over 80.1% on the same day, severely impacting shareholder investment value and potentially triggering further legal actions.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for discussions on protecting their rights, demonstrating the firm's commitment to supporting investor interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.365
Low
10.00
Averages
12.33
High
15.00
Current: 0.365
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Under Investigation for Possible Securities Law Violations
- Stock Price Plunge: On February 23, 2026, Gossamer Bio disclosed that its Phase 3 PROSERA study results failed to meet the primary endpoint, causing its stock price to plummet by 80.3% to close at $0.42 per share, severely impacting investor interests.
- Study Failure Impact: The study indicated that patients at Latin American sites performed well on placebo, reflecting a heavily-treated, lower-risk patient population, which exacerbated market concerns regarding the company's future prospects.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Gossamer Bio to assess potential violations of federal securities laws, which could lead to legal actions for investors seeking to recover losses.
- Investor Rights Protection: The law firm is urging all investors who suffered losses in Gossamer Bio to reach out to discuss potential claims, demonstrating a commitment to protecting investor rights and interests.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before class certification to ensure their rights are protected and avoid being absent class members.
See More
Faruqi & Faruqi Investigates Gossamer Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Gossamer Bio, Inc. for potential investor losses incurred between June 16, 2025, and February 20, 2026, indicating the company may face legal liabilities that could impact its market reputation.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the need for timely action to protect their rights, which could affect future claims outcomes.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330, demonstrating a commitment to supporting investor rights and concerns.
- Potential Claim Opportunities: This investigation may offer investors a chance to file claims, and if Gossamer is found to have engaged in wrongdoing, affected investors could receive compensation, further influencing the company's stock price and investor confidence.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Notification: DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ:GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, encouraging affected shareholders to contact the firm for potential lead plaintiff appointments.
- Lawsuit Timeline: The class period for the lawsuit spans from June 16, 2025, to February 20, 2026, with a deadline of June 1, 2026, by which shareholders must act to secure their rights in the case.
- False Statement Allegations: The complaint alleges that Gossamer misled investors by concealing critical facts regarding issues with its Phase 3 PROSERA study, rendering its public statements false and materially misleading throughout the class period, which has resulted in investor losses.
- Legal Service Advantage: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by June 1, 2026, highlighting serious governance concerns.
- Stock Price Plunge: Following the announcement of the PROSERA study results on February 23, 2026, which failed to meet primary endpoints, Gossamer's stock price plummeted by 80.13% to close at $0.42 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Failure: The Phase 3 PROSERA study conducted by Gossamer did not achieve its primary endpoint of improving six-minute walk distance at Week 24, despite a +13.3 meter placebo-adjusted gain, failing to meet the required 0.025 alpha threshold, indicating a significant clinical trial failure.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, suggesting that this case may attract broader legal scrutiny.
See More
Gossamer Bio Faces Class Action for Misleading Investors
- Class Action Filed: Robbins LLP reminds investors that a class action has been initiated on behalf of shareholders who purchased Gossamer Bio (NASDAQ:GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding its PROSERA study, resulting in inflated stock purchases.
- Study Results Fail: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Severe Investor Losses: Following the announcement, Gossamer's stock price dropped from $2.13 per share on February 20, 2026, to $0.42 per share, reflecting a significant loss of investor confidence and potentially exposing shareholders to substantial financial losses.
- Legal Action Follow-Up: Robbins LLP encourages affected shareholders to participate in the class action as lead plaintiffs, representing the interests of other class members, while also allowing non-participating shareholders to retain their rights to recovery, demonstrating a commitment to shareholder rights protection.
See More
Gossamer Bio Under Investigation for Possible Securities Law Violations
- Stock Price Plunge: On February 23, 2026, Gossamer Bio disclosed that its Phase 3 PROSERA study results failed to meet the primary endpoint, causing its stock price to plummet by 80.3% to close at $0.42 per share, severely impacting investor interests.
- Study Failure Impact: The study indicated that patients at Latin American sites performed well on placebo, reflecting a heavily-treated, lower-risk patient population, which exacerbated market concerns regarding the company's future prospects.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Gossamer Bio to assess potential violations of federal securities laws, which could lead to legal actions for investors seeking to recover losses.
- Investor Rights Protection: The law firm is urging all investors who suffered losses in Gossamer Bio to reach out to discuss potential claims, demonstrating a commitment to protecting investor rights and interests.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before class certification to ensure their rights are protected and avoid being absent class members.
See More
Faruqi & Faruqi Investigates Gossamer Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Gossamer Bio, Inc. for potential investor losses incurred between June 16, 2025, and February 20, 2026, indicating the company may face legal liabilities that could impact its market reputation.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the need for timely action to protect their rights, which could affect future claims outcomes.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330, demonstrating a commitment to supporting investor rights and concerns.
- Potential Claim Opportunities: This investigation may offer investors a chance to file claims, and if Gossamer is found to have engaged in wrongdoing, affected investors could receive compensation, further influencing the company's stock price and investor confidence.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Notification: DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ:GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, encouraging affected shareholders to contact the firm for potential lead plaintiff appointments.
- Lawsuit Timeline: The class period for the lawsuit spans from June 16, 2025, to February 20, 2026, with a deadline of June 1, 2026, by which shareholders must act to secure their rights in the case.
- False Statement Allegations: The complaint alleges that Gossamer misled investors by concealing critical facts regarding issues with its Phase 3 PROSERA study, rendering its public statements false and materially misleading throughout the class period, which has resulted in investor losses.
- Legal Service Advantage: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Gossamer Bio, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by June 1, 2026, highlighting serious governance concerns.
- Stock Price Plunge: Following the announcement of the PROSERA study results on February 23, 2026, which failed to meet primary endpoints, Gossamer's stock price plummeted by 80.13% to close at $0.42 per share, reflecting extreme market pessimism regarding the company's future prospects.
- Study Results Failure: The Phase 3 PROSERA study conducted by Gossamer did not achieve its primary endpoint of improving six-minute walk distance at Week 24, despite a +13.3 meter placebo-adjusted gain, failing to meet the required 0.025 alpha threshold, indicating a significant clinical trial failure.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, suggesting that this case may attract broader legal scrutiny.
See More
Gossamer Bio Faces Class Action for Misleading Investors
- Class Action Filed: Robbins LLP reminds investors that a class action has been initiated on behalf of shareholders who purchased Gossamer Bio (NASDAQ:GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding its PROSERA study, resulting in inflated stock purchases.
- Study Results Fail: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Severe Investor Losses: Following the announcement, Gossamer's stock price dropped from $2.13 per share on February 20, 2026, to $0.42 per share, reflecting a significant loss of investor confidence and potentially exposing shareholders to substantial financial losses.
- Legal Action Follow-Up: Robbins LLP encourages affected shareholders to participate in the class action as lead plaintiffs, representing the interests of other class members, while also allowing non-participating shareholders to retain their rights to recovery, demonstrating a commitment to shareholder rights protection.
See More
